Drug Pipeline
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
“Drug Pipeline”
22 result(s)
Care Management
The Promise and Questions of Aducanumab
Biogen’s new Alzheimer’s drug may be changing the treatment landscape, but lingering questions remain. More
Commentary
Drug Pipeline
Effective management strategies can help payors manage cost for a range of new treatment options in the drug pipeline. Several medications are nearing approvals for Alzheimer’s,... More
Briefing
Drug Pipeline
A range of new treatment options for AD are expected to come to market in the next couple years. Effective management strategies can help payors manage cost. More
Briefing
Specialty
Our proven strategies including step therapy, Specialty Guideline Management, and cross-benefit management can help clients better manage costs for the growing number of IBD... More
Feature
Drug Pipeline
Over the past dozen years, several new treatments have come to market with the first oral preventive expected to be approved in December. Targeted management to help balance... More
Feature
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for... More
White Paper
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature